MARKET

CYTR

CYTR

Cytrx
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.155
+0.025
+19.15%
Opening 09:56 05/20 EDT
OPEN
0.130
PREV CLOSE
0.130
HIGH
0.155
LOW
0.130
VOLUME
6.30K
TURNOVER
944
52 WEEK HIGH
4.700
52 WEEK LOW
0.094
MARKET CAP
6.01M
P/E (TTM)
-1.0320
1D
5D
1M
3M
1Y
5Y
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
LOS ANGELES, May 17, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by Ke...
Business Wire · 3d ago
CytRx Partners with Oncology Development Expert to Advance LADR Platform
LOS ANGELES, April 20, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert...
Business Wire · 04/20 12:00
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
LOS ANGELES, March 21, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to stockholders.
Business Wire · 03/21 12:00
Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce
Benzinga · 03/11 15:42
CytRx to absorb subsidiary Centurion BioPharma; former CEO retires from board
CytRx (OTCQB:CYTR) said it is absorbing its subsidiary Centurion BioPharma to bring efficiency and simplicity to its structure. Centurion's assets — which consists of LADR platform being developed for localized
Seekingalpha · 03/09 17:24
CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates
LOS ANGELES, March 09, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that the Company is absorbing its wholly-owned su...
Business Wire · 03/09 13:00
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES, February 24, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDA...
Business Wire · 02/24 13:00
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
LOS ANGELES, February 14, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted Orphazyme A/S's (NASDAQ...
Business Wire · 02/14 13:00
More
No Data
Learn about the latest financial forecast of CYTR. Analyze the recent business situations of Cytrx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CYTR stock price target is 4.500 with a high estimate of 4.500 and a low estimate of 4.500.
High4.500
Average4.500
Low4.500
Current 0.1549
EPS
Actual
Estimate
-0.06-0.05-0.03-0.02
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 9
Institutional Holdings: 1.12M
% Owned: 2.89%
Shares Outstanding: 38.80M
TypeInstitutionsShares
Increased
1
86.05K
New
0
0
Decreased
0
0
Sold Out
27
1.65M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.55%
Pharmaceuticals & Medical Research
+0.91%
Key Executives
Chairman/Director
Louis Ignarro
Chief Executive Officer
Stephen Snowdy
Chief Financial Officer/Chief Accounting Officer/IR Contact Officer
John Caloz
Independent Director
Joel Caldwell
Independent Director
Jennifer Simpson
No Data
No Data
About CYTR
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Webull offers kinds of CytRx Corporation stock information, including OTCMQB:CYTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTR stock methods without spending real money on the virtual paper trading platform.